AGP: 2QCY26 EPS clocked in at PKR 2.15, down 3%YoY

Flashnote: Pharmaceutical – AGP Limited (AGP) – 2QCY26 Result Review

Monday, August 24, 2026

- **Board Meeting:** August 21, 2026
- **2QCY26:** EPS: PKR 2.15, PAT: PKR 586Mn, down ~8%YoY/39%QoQ, Dividend: PKR 2/sh.
- In 2QCY26, AGP recorded revenue of PKR 4.7Bn, down 16%YoY and 32%QoQ, primarily due to lower sales amid reduced viral diseases demand driven by seasonal impact, along with disruptions in exports to Afghanistan. Gross margins improved by 3ppts YoY and QoQ driven by efficient cost controls and favorable API prices.
- Effective tax rate declined significantly by 75%YoY and 79%QoQ to ~7%, primarily due to a lower current tax charge coupled with a deferred tax credit. Hence, PAT arrived at PKR 586Mn, down 8%YoY and 39%QoQ primarily due to lower sales, resulting in an EPS of PKR 2.15/sh. Finally, AGP has announced an interim dividend of PKR 2/sh, for the quarter.

AGP Result Review - 2QCY26 - Consolidated

PKR Mn	2QCY26A	2QCY25A	YoY	1QCY26A	QoQ	1HCY26A	1HCY25A	YoY
Revenue	4,676	5,558	-16%	6,850	-32%	11,526	12,717	-9%
Cost of Sales	(1,815)	(2,302)	-21%	(2,857)	-36%	(4,673)	(5,338)	-12%
Gross Profit	2,860	3,256	-12%	3,993	-28%	6,853	7,379	-7%
Selling, Admin & Marketing Expenses	(1,858)	(1,922)	-3%	(2,080)	-11%	(3,938)	(3,863)	2%
Other Expenses/(Income) - net	(25)	(61)	-59%	(85)	-71%	(110)	(110)	0%
Finance Costs	(344)	(362)	-5%	(316)	9%	(660)	(747)	-12%
Profit Before Tax	633	911	-30%	1,511	-58%	2,144	2,659	-19%
Taxation	(47)	(275)	-83%	(542)	-91%	(589)	(967)	-39%
Profit After Tax	586	636	-8%	968	-39%	1,555	1,692	-8%
Profit attributable to Parent Co.	601	617	-3%	857	-30%	1,458	1,470	-1%
EPS	2.15	2.20		3.06		5.21	5.25	
DPS	2.00	2.00		NIL		2.00	2.00	

Source: Company Accounts & TSL Research

SECP Research Entity Notification Number: REP-040

Analyst Certification

The research analyst(s), if any, denoted by AC on the cover of this report, who exclusively reports to the research department head, primarily involved in the preparation, writing and publication of this report, certifies that (1) the views expressed in this report are unbiased and independent opinions of the Research Analyst which accurately reflect his/her personal views about all of the subject companies/securities and (2) no part of his/her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

The research analyst or any of its financially dependent close relatives (as defined under the Research Analyst Regulations, 2015) do not have a financial interest in the securities of the subject company aggregating more than 1% of the value of the company and the research analyst or its close relative have neither served as a director/officer in the past 3 years nor received any compensation from the subject company in the past 12 months.
The Research analyst or its close relatives have not traded in the subject security in the past seven (7) days prior to the publication of this research report and will not trade contrary to the recommendation until the target price is achieved, unless a revised research report is disseminated through the same medium, in accordance with applicable regulations.

Disclaimer

This report has been prepared by Taurus Securities Ltd (hereinafter referred as TSL) and is provided for information purposes only. Under no circumstances is to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such.

This report is provided solely for the information of professional advisers who are expected to make their own investment decisions without undue reliance on this report. Statements regarding future prospects may not be realized while all such information and opinions are subject to change without notice. TSL recommends investors to independently evaluate particular investments and strategies and it encourages investors to seek the advice of a financial advisor.
Investments in capital markets are subject to market risk and TSL accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. In particular, the report takes no account of the investment objectives, financial situation and particular needs of individuals, who should seek further advice before making any investment or rely upon their own judgment and acumen before making any investment. The views expressed in this document are those of the TSL Research Department and do not necessarily reflect those of TSL or its directors.
This research report has been prepared in a fiduciary capacity towards clients and in compliance with the Research Analyst Regulations, 2015 as amended. TSL may, to the extent permissible by applicable law or regulation, use the above material, conclusions, research or analysis in which they are based before the material is disseminated to their customers.

TSL, as a full-service firm, has/intends to have business relationships, including investment-banking relationships, with the companies in this report. Investors should be aware that TSL may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. TSL claims responsibility for Research or other publication disseminating ONLY through its official channels (email address, TSL Web etc.) and DOES NOT take ownership/responsibility for report(s) circulated through other sources (social media, website, blogs etc.) under the name of the organization. TSL Management reserves the right to take action against unauthorized reproduction, distribution or publication of its reports.

Disclosure of Financial Interest

TSL or any of its officers and directors does not have a significant financial interest (above 1% of the value of the securities of the subject company) in the securities of the subject company. However, NBP and BOK, being associates of TSL, may trade or have significant financial interest, under normal course of business, in the subject company from time to time. Under normal course of business, TSL, their respective directors, officers, representatives, employees and/or persons associated with research analyst may have a long or short position in any of the securities or other financial instruments mentioned or issues described herein at any time and may make a purchase and/or sale, or offer to make a purchase and/or sale of any such securities or other financial instruments from time to time in the open market or otherwise. TSL or its employees may trade contrary to the recommendation given by TSL Research through this report or any other only in accordance with applicable regulatory restrictions. TSL may be providing, or have provided within the previous twelve months, significant advice or brokerage services to the subject company. TSL may have, within the past twelve months, served as manager or co-manager of a public offering of securities for, or currently may make a primary market in issues of, any or all, the entities mentioned in this report or received compensation for corporate advisory services, brokerage services or underwriting services from the subject company. TSL or any other of its officers and directors have neither served as a director/officer in any company under TSL research coverage in the past 3 years nor received any compensation from the subject company in the past 12 months.

Taurus Stock Rating System

TSL employs a 3-tier rating mechanism i.e 'BUY', 'HOLD' and 'SELL', which is based upon the level of expected return for a specific stock. When total return (capital gain + dividends) exceeds 16%, a 'BUY' rating is assigned. A 'SELL' rating is issued whenever total return is less than -6% and for return in between the 2 ranges, 'HOLD' rating is meted out. Different securities firms use a variety of rating terms/systems to describe their recommendations. Similar rating terms used by other securities companies may not be equivalent to TSL rating system. Time horizon is usually the annual financial reporting period of the company (unless otherwise mentioned in the report). Ratings are updated daily and can therefore change daily. They can change because of a move in the stock's price, a change in the analyst's estimate of the stock's fair value, a change in the analyst's assessment of a company's business risk, or a combination of any of these factors. In addition, research reports contain information carrying the analyst's views and investors should carefully read the entire research report and not infer its contents from the rating ascribed by the analyst. In any case, ratings or research should not be used or relied upon as investment advice. An investor's decision to buy, sell or hold a stock should depend on individual circumstances (such as the investors existing holdings or investment objectives) and other considerations.

Target Price and Risk Disclosures

Any inability to compete successfully in the markets may harm the business. This could be a result of many factors which may include (but not limited to) geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company may enter into transactions, including transactions in derivative instruments, to manage/offset certain of these exposures. Where a target price is provided, the valuation methodology used to determine such target price has a reasonable basis and is accompanied by material risk disclosures that may impede achievement of the target price. The report clearly discloses the target price and the target date on which such target price is expected to be achieved. z

Flashnote: Pharmaceutical – AGP Limited (AGP) – 2QCY26 Result Review

Monday, August 24, 2026

Valuation Methodology

To arrive at our period end target prices, TSL uses different valuation methodologies including
- Discounted cash flow (DCF, DDM)
- Justified price to book (JPB)
- Relative Valuation (P/E, P/B, P/S, EV/EBITDA, EV/Revenue etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)

SECP JamaPunji Portal link: https://jamapunji.pk/

Frequently Used Acronyms

TP	Target Price	**DCF**	Discounted Cash Flow	**FCF**	Free Cash Flows
FCFE	Free Cash Flows to Equity	**FCFF**	Free Cash Flows to Firm	**DDM**	Dividend Discount Model
SOTP	Sum of the Parts	**P/E**	Price to Earnings ratio	**P/BVPS**	Price to Book ratio
P/S	Price to Sales	**EVA**	Economic Valued Added	**BVPS**	Book Value per Share
EPS	Earnings per Share	**DPS**	Dividend per Share	**DY**	Dividend Yield
ROE	Return on Equity	**ROA**	Return on Assets	**JPB**	Justified Price to Book

Distribution of Research

This research report is disseminated in a non-selective manner to eligible clients and is not distributed selectively to any internal trading personnel or a particular client or class of clients in advance of others entitled to receive it.

Artificial Intelligence (AI) Disclosure

This research report may utilize artificial intelligence (AI) tools to assist in data processing, analysis, or drafting. The extent of use of AI tools does not replace human judgment, and the final content, conclusions, and recommendations are reviewed, validated, and approved by the Research Analyst(s).